Welcome! It's on Saturday 23rd August 2014


  • Exenatide improves quality of life & weight loss

    Exenatide improves quality of life & weight loss

    Bydureon® (exenatide once-weekly injection) can achieve better glycaemic control with weight loss and less hypoglycaemia, compared to treatment with insulin glargine, over three years, finds new research.

  • DUAL trial points to benefits for Type 2

    Data presented today at the Diabetes UK conference in Liverpool, as part of the Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes studies (DUAL™ I and II), demonstrate that Novo Nordisk’s novel, once-daily Type 2 diabetes treatment IDegLira results in a significantly greater reduction (1.91%) in blood sugar levels (HbA1c) versus basal insulin degludec (IDeg) Tresiba® (1.44%; p<0.0001) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) liraglutide (Victoza®) alone (1.28%; p<0.0001).

  • Avastin trials may lead to breakthrough

    New data showing cancer treatment Avastin® (bevacizumab, Roche) can extend the lives of women with advanced cervical cancer compared to chemotherapy alone has been published in the New England Journal of Medicine.